Ligand (LGND) CLO Andrew Reardon Sells 5,000 Shares

What Happened Andrew Reardon, Chief Legal Officer and Secretary of Ligand Pharmaceuticals (LGND), sold a total of 5,000 shares in open‑market transactions on September 3, 2026, for aggregate proceeds of approximately $1,430,435. The sales were reported as disposals (transaction code S) in five blocks: 300 shares @ $283.99 ($85,196), 1,800 shares @ $285.17 ($513,301), 2,115 shares @ $286.36 ($605,649), 385 shares @ $287.53 ($110,697), and 400 shares @ $288.98 ($115,592).

Key Details

• Transaction date: September 3, 2026 (filed on September 8, 2026).
• Aggregate shares sold: 5,000; aggregate proceeds: ~$1.43 million.
• Prices shown are weighted averages; the reported ranges per lot were:
  • 300 shares: $283.43–$284.155 (weighted avg $283.99)
  • 1,800 shares: $284.75–$285.70 (weighted avg $285.17)
  • 2,115 shares: $285.80–$286.77 (weighted avg $286.36)
  • 385 shares: $287.05–$287.66 (weighted avg $287.53)
  • 400 shares: $288.55–$289.43 (weighted avg $288.98)
• The sales were made pursuant to a written Rule 10b5‑1 trading plan adopted by the reporting person on June 4, 2026 (see footnote).
• Shares owned after the transactions are not shown in the supplied summary of the filing.
• Filing timeliness: The Form 4 was filed five days after the trades (Sept. 8 vs. Sept. 3); Form 4s are generally required within two business days, so this appears later than the usual deadline.

Context

• These were open‑market sales under a pre‑arranged 10b5‑1 plan, which typically allows insiders to sell according to a predetermined schedule and can limit the inference you can draw about the insider's current view of the company. Sales are common for tax or diversification reasons and do not necessarily indicate negative company expectations. Purchases tend to be more informative about insider confidence.